Chevron, Eli Lilly, Honeywell, PhD Health

“I like Chevron because I think oil is still undervalued even after last year. Oil has a new discipline,” Kramer said.He also pointed out that in September, Chevron Announce plan Triple its capital investment in the low-carbon energy sector. Chevron has risen by nearly 42% in the past 12 months and has risen by more than 5% by 2022.

Cramer highlighted Eli Lilly’s experimental Alzheimer’s treatment method, called donanemab, and a diabetes drug called tirzepatide. Kramer said that another reason he was attracted to Eli Lilly stock was because he felt that the overall sentiment towards the pharmaceutical company was too negative. Although Lilly has gained nearly 59% in the past 12 months, the stock has a slow start in the first three trading days of 2022 and has fallen by about 5% so far this year.

Kramer said he is optimistic about the industrial conglomerate Honeywell, but noted that it usually lags behind its peers in taking upward moves. In the past 12 months, the stock’s share price was approximately 2.6%. It has a good start in 2022, with an increase of about 2.55% so far this year.

In the episode of “Crazy Money” on Tuesday, Kramer said he Wall Street is expected to be tolerant this year For Honeywell and other stocks and other industrial names such as Deere Company and Boeing“At this moment in the business cycle, the script says you have to work with more tangible companies that make real things and generate real profits,” Kramer said on Tuesday.

Kramer Charitable Trust Started working at Bausch Health On December 20, the healthy stock exposure of the portfolio was increased. Early Wednesday, The trust raised the target price of Bausch Health stock from $29 to $36. Bausch Health’s share price will be basically flat from 2022. However, in the past 12 months, the stock has risen by more than 26%.

In the “Halftime Report,” Cramer touted Bausch Health’s plan to split itself into three different entities, including a company focused on eye health, a medical beauty department, and a diversified pharmaceutical company. “I like a big breakup story,” he said. In the planned split of Johnson & Johnson, General Electric and PhD students, I like the health of PhD students as the best split,” he added.

Sign up now Let CNBC Investment Club follow Jim Cramer’s every move in the market.
Disclosure: Kramer’s charitable trust owns Chevron, Honeywell, Eli Lilly and PhD Health.